Consequence of HIV and HCV co-infection on host immune response, persistence and current treatment options

Area of Science:

• * Hepatology and Virology
• * Immunology and Infectious Diseases

Background:

• * Hepatitis C virus (HCV) is an opportunistic pathogen frequently co-infecting Human Immunodeficiency Virus (HIV)-positive individuals.
• * The impact of HCV on HIV disease progression is debated, with some studies showing no effect and others indicating accelerated Acquired Immunodeficiency Syndrome (AIDS)-related morbidity and mortality.
• * Management challenges in HIV/HCV co-infection include impaired HCV antibody response, drug interactions, liver disease, and distinct epidemiological factors.

Purpose of the Study:

• * To review the consequences of HIV/HCV co-infection on immune response, viral replication, and disease progression.
• * To discuss the impact on mortality, morbidity, viral load, and persistence.
• * To evaluate current treatment strategies for HIV/HCV co-infected patients.

Main Methods:

• * This is a review article synthesizing findings from existing clinical studies on HIV/HCV co-infection.
• * Analysis of host immune response, viral characteristics, and disease progression markers.
• * Examination of treatment outcomes and therapeutic recommendations.

Main Results:

• * Morbidity and mortality associated with HCV have risen since the advent of highly active antiretroviral therapy (HAART) for HIV.
• * Co-infection significantly impacts host immune status and viral dynamics.
• * The interplay between HCV and HIV complicates treatment decisions and patient management.

Conclusions:

• * Evaluating the effect of HCV therapy on HIV progression is crucial.
• * Active HCV treatment is necessary for patients undergoing HIV therapy.
• * Combination therapy with fully active HAART and established HCV treatment is recommended.